AASLD/EASL Special Conference on Hepatitis C New York City, New York September 12

Conference Reports for NATAP


AASLD/EASL Special Conference on Hepatitis C New York City, New York September 12 - 13

	Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Telaprevir (TVR) in Combination with Sofosbuvir (SOF) in Treatment-naïve Patients with Genotype 1 Hepatitis C Virus Infection - (11/21/14) Changes in Intrahepatic, Endogenous Interferon Expression in Chronic HCV, Genotype-1 Patients Treated with Interferon-free, Ribavirin-Free DAA Regimens - (11/20/14) AASLD/IDSA Guidelines Improves Restrictions Language - (10/31/14) Preclinical Characterization of AL-335, a Potent Uridine Based Nucleoside Polymerase Inhibitor for the Treatment of Chronic Hepatitis C - (10/15/14) Most patients with HCV-associated lymphoma present with mild liver disease at cancer diagnosis: A call to revise indications for HCV treatment - (09/26/14) Outcome analysis of ledipasvir/sofosbuvir (LDV/SOF) for the treatment of chronic hepatitis C infected genotype 1 patients in the UK. - (09/26/14) The Optimal HCV All-Oral Cocktail HCV genotypes 4,5 & 6 and Mixology - (09/19/14) Changing Epidemiology of HCV Infection: Unsafe Injections and Other Modes of Transmission (prevention/screening/heroin/cascade of care/IDUs - (09/15/14) Therapeutic Challenges: Decompensated Cirrhosis and Liver Transplantation - (09/15/14) Real World Experience with DAA Regimens - Phase 4 HCV TARGET Study - (09/15/14)